Literature DB >> 22498766

Regulatory T cells in atherogenesis.

Naoto Sasaki1, Tomoya Yamashita, Masafumi Takeda, Ken-ichi Hirata.   

Abstract

Atherosclerosis is believed to be an inflammatory condition of the arterial wall. It has become apparent that various types of cells of innate and adaptive immunity participate in atherogenesis. T cells are of particular interest because they mediate pathogenic immune responses involved in the acceleration of atherosclerosis. Recent studies from several independent groups indicated that subsets of regulatory T cells (Tregs) actively mediate immunologic tolerance and inhibit atherosclerosis development or progression through the down-regulation of effector T-cell responses. It is likely that there is an imbalance between pathogenic effector T cells and Tregs under atherosclerotic conditions. Recent evidence suggests that in addition to the thymus, gut-associated lymphoid tissues are the main sites for the generation of several subsets of peripherally inducible Tregs. This indicates that intervention in the gut environment to promote an endogenous regulatory immune response may serve as a possible therapeutic approach to suppress atherosclerotic diseases. In this review, we discuss not only the possible role of Tregs in the prevention of atherosclerosis, but also promising strategies to prevent or cure atherosclerotic diseases by promoting an endogenous regulatory immune response, particularly by oral immune modulation.

Entities:  

Mesh:

Year:  2012        PMID: 22498766     DOI: 10.5551/jat.10934

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  15 in total

1.  Regulatory T cells and Atherosclerosis.

Authors:  Jahaira Lopez Pastrana; Xiaojin Sha; Anthony Virtue; Jietang Mai; Ramon Cueto; In Ae Lee; Hong Wang; Xiao-Feng Yang
Journal:  J Clin Exp Cardiolog       Date:  2012-10-08

2.  Inhibiting DNA Methylation by 5-Aza-2'-deoxycytidine ameliorates atherosclerosis through suppressing macrophage inflammation.

Authors:  Qiang Cao; Xianfeng Wang; Lin Jia; Ashis K Mondal; Abdoulaye Diallo; Gregory A Hawkins; Swapan K Das; John S Parks; Liqing Yu; Huidong Shi; Hang Shi; Bingzhong Xue
Journal:  Endocrinology       Date:  2014-09-24       Impact factor: 4.736

Review 3.  Stabilization of high-risk plaques.

Authors:  Kohei Takata; Satoshi Imaizumi; Bo Zhang; Shin-Ichiro Miura; Keijiro Saku
Journal:  Cardiovasc Diagn Ther       Date:  2016-08

4.  Amelioration of Atherosclerosis by the New Medicinal Mushroom Grifola gargal Singer.

Authors:  Etsuko Harada; Corina N D'Alessandro-Gabazza; Masaaki Toda; Toshihiro Morizono; Ayshwarya-Lakshmi Chelakkot-Govindalayathil; Ziaurahman Roeen; Masahito Urawa; Taro Yasuma; Yutaka Yano; Toshimitsu Sumiya; Esteban C Gabazza
Journal:  J Med Food       Date:  2015-03-23       Impact factor: 2.786

5.  Caveolin-1 Promotes the Imbalance of Th17/Treg in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Nina Sun; Xiaofang Wei; Jingluan Wang; Zhaozhong Cheng; Weihong Sun
Journal:  Inflammation       Date:  2016-12       Impact factor: 4.092

Review 6.  T helper cell polarization in healthy people: implications for cardiovascular disease.

Authors:  Nels C Olson; Reem Sallam; Margaret F Doyle; Russell P Tracy; Sally A Huber
Journal:  J Cardiovasc Transl Res       Date:  2013-08-07       Impact factor: 4.132

Review 7.  Epigenetic enzymes are the therapeutic targets for CD4(+)CD25(+/high)Foxp3(+) regulatory T cells.

Authors:  Jahaira Lopez-Pastrana; Ying Shao; Valeria Chernaya; Hong Wang; Xiao-Feng Yang
Journal:  Transl Res       Date:  2014-08-15       Impact factor: 7.012

8.  Decreased naive and increased memory CD4(+) T cells are associated with subclinical atherosclerosis: the multi-ethnic study of atherosclerosis.

Authors:  Nels C Olson; Margaret F Doyle; Nancy Swords Jenny; Sally A Huber; Bruce M Psaty; Richard A Kronmal; Russell P Tracy
Journal:  PLoS One       Date:  2013-08-23       Impact factor: 3.240

9.  CD3 antibody and IL-2 complex combination therapy inhibits atherosclerosis by augmenting a regulatory immune response.

Authors:  Kazuyuki Kasahara; Naoto Sasaki; Tomoya Yamashita; Tomoyuki Kita; Keiko Yodoi; Yoshihiro Sasaki; Masafumi Takeda; Ken-Ichi Hirata
Journal:  J Am Heart Assoc       Date:  2014-04-22       Impact factor: 5.501

10.  Pathological conditions re-shape physiological Tregs into pathological Tregs.

Authors:  William Y Yang; Ying Shao; Jahaira Lopez-Pastrana; Jietang Mai; Hong Wang; Xiao-Feng Yang
Journal:  Burns Trauma       Date:  2015-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.